[go: up one dir, main page]

NO20022065D0 - Terapeutisk anvendelse - Google Patents

Terapeutisk anvendelse

Info

Publication number
NO20022065D0
NO20022065D0 NO20022065A NO20022065A NO20022065D0 NO 20022065 D0 NO20022065 D0 NO 20022065D0 NO 20022065 A NO20022065 A NO 20022065A NO 20022065 A NO20022065 A NO 20022065A NO 20022065 D0 NO20022065 D0 NO 20022065D0
Authority
NO
Norway
Prior art keywords
therapeutic use
patient
chemoprevention
onset
effective amount
Prior art date
Application number
NO20022065A
Other languages
English (en)
Other versions
NO323206B1 (no
NO20022065L (no
Inventor
Nigel James Bundred
Original Assignee
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manchester filed Critical Univ Manchester
Publication of NO20022065D0 publication Critical patent/NO20022065D0/no
Publication of NO20022065L publication Critical patent/NO20022065L/no
Publication of NO323206B1 publication Critical patent/NO323206B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20022065A 1999-11-02 2002-04-30 Anvendelse av EGFR-tyrosinkinase-inhibitor for fremstilling av et medikament, og et medisinsk testsett som omfatter en EGFR-tyrosinkinase-inhibitor NO323206B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9925958.2A GB9925958D0 (en) 1999-11-02 1999-11-02 Therapeutic use
PCT/GB2000/004190 WO2001032155A2 (en) 1999-11-02 2000-11-01 Use of egfr tyrosine kinase inhibitors for treating breast cancer

Publications (3)

Publication Number Publication Date
NO20022065D0 true NO20022065D0 (no) 2002-04-30
NO20022065L NO20022065L (no) 2002-06-24
NO323206B1 NO323206B1 (no) 2007-01-22

Family

ID=10863835

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20022065A NO323206B1 (no) 1999-11-02 2002-04-30 Anvendelse av EGFR-tyrosinkinase-inhibitor for fremstilling av et medikament, og et medisinsk testsett som omfatter en EGFR-tyrosinkinase-inhibitor

Country Status (21)

Country Link
US (1) US7553815B1 (no)
EP (1) EP1272188B1 (no)
JP (1) JP2003513035A (no)
KR (1) KR100785359B1 (no)
CN (1) CN1197577C (no)
AT (1) ATE339957T1 (no)
AU (1) AU779190B2 (no)
BR (1) BR0015194A (no)
CA (1) CA2389411C (no)
CY (1) CY1106285T1 (no)
DE (1) DE60030889T2 (no)
DK (1) DK1272188T3 (no)
ES (1) ES2275556T3 (no)
GB (1) GB9925958D0 (no)
IL (1) IL149176A0 (no)
MX (1) MXPA02004272A (no)
NO (1) NO323206B1 (no)
NZ (1) NZ518696A (no)
PT (1) PT1272188E (no)
WO (1) WO2001032155A2 (no)
ZA (1) ZA200203431B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CN109395082A (zh) 2000-05-19 2019-03-01 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
US7132427B2 (en) 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
JP2005507424A (ja) * 2001-10-29 2005-03-17 ノバルティス アクチエンゲゼルシャフト 固形腫瘍の処置における７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体の使用
SI2305255T1 (sl) * 2001-12-03 2012-10-30 Bayer Healthcare Llc Arilsečninske spojine v kombinaciji z drugimi citostatičnimi ali citotoksičnimi sredstvi za zdravljenje človeških rakov
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
DK1509230T3 (da) * 2002-06-05 2007-05-14 Cedars Sinai Medical Center Gefitinib ( IRESSA) til behandlingen af cancer
WO2005017493A2 (en) * 2003-08-15 2005-02-24 Smithkline Beecham Corporation Biomarkers in cancer
ES2279441T3 (es) 2003-09-19 2007-08-16 Astrazeneca Ab Derivados de quinazolina.
WO2005039588A2 (en) * 2003-10-22 2005-05-06 Novartis Ag Methods for determining the risk of developing liver and lung toxicity
US7701341B2 (en) * 2004-09-01 2010-04-20 Microsoft Corporation Device service provider interface
EP1846030B1 (en) 2005-01-21 2018-11-21 Genentech, Inc. Fixed dosing of her antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
CN101003514A (zh) 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
CN101415422B (zh) 2006-02-09 2012-11-07 第一三共株式会社 抗癌药用组合物
CN1899616A (zh) * 2006-07-20 2007-01-24 中国人民解放军军事医学科学院生物工程研究所 非受体酪氨酸激酶c－Abl特异性抑制剂的新用途
MX2009008981A (es) 2007-03-02 2009-09-02 Genentech Inc Prediccion de respuesta a un inhibidor her.
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2008154249A2 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
MA33091B1 (fr) 2009-03-11 2012-03-01 Ardea Biosciences Inc Combinaisons pharmaceutiques comprenant rdea119/bay 869766 pour le traitement de cancers specifiques
KR20130080871A (ko) 2009-03-20 2013-07-15 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
EP2435071A1 (en) 2009-05-29 2012-04-04 F. Hoffmann-La Roche AG Modulators for her2 signaling in her2 expressing patients with gastric cancer
SI2536748T1 (sl) 2010-02-18 2014-12-31 Genentech, Inc. Nevrogulinski antagonisti in njihova uporaba pri zdravljenju raka
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
WO2013025853A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Neuregulin antibodies and uses thereof
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
JP2015500638A (ja) 2011-11-30 2015-01-08 ジェネンテック， インコーポレイテッド 癌におけるｅｒｂｂ３変異
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
CA2865082A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
MX363188B (es) 2012-11-30 2019-03-13 Hoffmann La Roche Identificación de pacientes con necesidad de coterapia del inhibidor de pd-l1.
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
EP3103799B1 (en) * 1995-03-30 2018-06-06 OSI Pharmaceuticals, LLC Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
WO1996040142A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
SI9620103A (sl) * 1995-07-06 1998-10-31 Novartis Ag Pirolopirimidini in postopki za njihovo pripravo
SK17282000A3 (sk) * 1998-05-15 2002-04-04 Imclone Systems Incorporated Nerádioaktívne označený inhibítor proteínového tyrozínkynázového receptora
JP2010503056A (ja) 2006-08-28 2010-01-28 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 画像の強調の方法及び装置

Also Published As

Publication number Publication date
CY1106285T1 (el) 2011-10-12
NO323206B1 (no) 2007-01-22
NZ518696A (en) 2004-12-24
BR0015194A (pt) 2002-06-18
KR100785359B1 (ko) 2007-12-18
DK1272188T3 (da) 2007-01-29
IL149176A0 (en) 2002-11-10
EP1272188B1 (en) 2006-09-20
DE60030889T2 (de) 2007-04-05
KR20020064306A (ko) 2002-08-07
MXPA02004272A (es) 2003-08-20
NO20022065L (no) 2002-06-24
EP1272188A2 (en) 2003-01-08
AU1155901A (en) 2001-05-14
PT1272188E (pt) 2007-01-31
CN1387437A (zh) 2002-12-25
ZA200203431B (en) 2003-02-26
US7553815B1 (en) 2009-06-30
WO2001032155A2 (en) 2001-05-10
CA2389411C (en) 2009-09-01
AU779190B2 (en) 2005-01-13
DE60030889D1 (de) 2006-11-02
GB9925958D0 (en) 1999-12-29
ATE339957T1 (de) 2006-10-15
CN1197577C (zh) 2005-04-20
ES2275556T3 (es) 2007-06-16
WO2001032155A3 (en) 2002-05-10
JP2003513035A (ja) 2003-04-08
CA2389411A1 (en) 2001-05-10

Similar Documents

Publication Publication Date Title
NO20022065D0 (no) Terapeutisk anvendelse
TR200201442T2 (tr) Ağrı hafifletme, kemik kanseri terapisi ve kemik yüzeyinin sağlıklı tutulması için kireçlenmiş hedef dokulara yönelik radyum-223 hazırlanması ve kullanımı.
EG25822A (en) Quinolinyl-pyrrolopyrazoles
ATE307601T1 (de) Brustkrebsbehandlung mittels natürlicher ätherischer öle
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
PT1223980E (pt) Utilizacao de inibidores de csf-1
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
NO20032027L (no) Effektive antitumorbehandlinger
SE9802208D0 (sv) Novel compounds
SE0300098D0 (sv) Use of cyclin D1 inhibitors
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
DE60111515D1 (de) Kombinationstherapie mit keratinozyten-wachstumfaktor und ein epidermis-wachstumfaktor inhibitor
ATE313334T1 (de) Behandlung von tumoren mit photodynamischer therapie
SE9802209D0 (sv) Novel compounds
SE9902597D0 (sv) New use
MX2007006927A (es) Combinacion de inhibidor de tirosina cinasa y her-2/neu para terapia de cancer.
ATE330600T1 (de) Kombinationspräparat zur krebstherapie
ITTO20000441A0 (it) Composizione terapeutica per la cura della psoriasi.
DE60234995D1 (de) Tatakrebs
ITPD20020003A1 (it) Biomateriali a base di acido ialuronico come terapia anti-angiogenicanella cura dei tumori.
DE60316927D1 (de) Verwendung von devazepide als schmerzmittel
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей
UA40393A (uk) Спосіб лікування хронічного обструктивного бронхіту

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees